KSHV infection of B cells primes protective T cell responses in humanized mice.
Animals
Herpesvirus 8, Human
/ immunology
Humans
B-Lymphocytes
/ immunology
Mice
CD8-Positive T-Lymphocytes
/ immunology
Epstein-Barr Virus Infections
/ immunology
Coinfection
/ immunology
CD4-Positive T-Lymphocytes
/ immunology
Herpesvirus 4, Human
/ immunology
Herpesviridae Infections
/ immunology
Immunoglobulin M
/ immunology
Antigens, Viral
/ immunology
Mice, SCID
Lymphoma, Primary Effusion
/ immunology
Antibodies, Viral
/ immunology
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
06 Jun 2024
06 Jun 2024
Historique:
received:
03
07
2023
accepted:
24
05
2024
medline:
7
6
2024
pubmed:
7
6
2024
entrez:
6
6
2024
Statut:
epublish
Résumé
Kaposi sarcoma associated herpesvirus (KSHV) is associated with around 1% of all human tumors, including the B cell malignancy primary effusion lymphoma (PEL), in which co-infection with the Epstein Barr virus (EBV) can almost always be found in malignant cells. Here, we demonstrate that KSHV/EBV co-infection of mice with reconstituted human immune systems (humanized mice) leads to IgM responses against both latent and lytic KSHV antigens, and expansion of central and effector memory CD4
Identifiants
pubmed: 38844783
doi: 10.1038/s41467-024-49209-w
pii: 10.1038/s41467-024-49209-w
doi:
Substances chimiques
Immunoglobulin M
0
Antigens, Viral
0
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4841Informations de copyright
© 2024. The Author(s).
Références
Cohen, J. I., Fauci, A. S., Varmus, H. & Nabel, G. J. Epstein-Barr virus: an important vaccine target for cancer prevention. Sci. Transl. Med 3, 107fs7 (2011).
pubmed: 22049067
pmcid: 3501269
doi: 10.1126/scitranslmed.3002878
Parkin, D. M. The global health burden of infection-associated cancers in the year 2002. Int J. Cancer 118, 3030–3044 (2006).
pubmed: 16404738
doi: 10.1002/ijc.21731
Münz, C. Latency and lytic replication in Epstein–Barr virus-associated oncogenesis. Nat. Rev. Microbiol. 17, 691–700 (2019).
pubmed: 31477887
doi: 10.1038/s41579-019-0249-7
Böni, M., Rieble, L. & Münz, C. Co-Infection of the Epstein–Barr Virus and the Kaposi Sarcoma-Associated Herpesvirus. Viruses 14, 2709 (2022).
pubmed: 36560713
pmcid: 9782805
doi: 10.3390/v14122709
Cesarman, E., Chadburn, A. & Rubinstein, P. G. KSHV/HHV8-mediated hematologic diseases. Blood 139, 1013–1025 (2022).
pubmed: 34479367
pmcid: 8854683
doi: 10.1182/blood.2020005470
Wong, Y., Meehan, M. T., Burrows, S. R., Doolan, D. L. & Miles, J. J. Estimating the global burden of Epstein–Barr virus-related cancers. J. Cancer Res Clin. Oncol. 148, 31–46 (2022).
pubmed: 34705104
doi: 10.1007/s00432-021-03824-y
Shen, J. et al. Incidence and trend of Epstein-Barr virus-related cancer: A surveillance, epidemiology, and end results program based study. J. Clin. Oncol. 39, 10575–10575 (2021).
doi: 10.1200/JCO.2021.39.15_suppl.10575
Cesarman, E. Gammaherpesviruses and lymphoproliferative disorders. Annu. Rev. Pathol.: Mechanisms Dis. 9, 349–372 (2014).
doi: 10.1146/annurev-pathol-012513-104656
Cesarman, E. et al. Kaposi sarcoma. Nat. Rev. Dis. Prim. 5, 9 (2019).
pubmed: 30705286
doi: 10.1038/s41572-019-0060-9
Gottschalk, S., Rooney, C. M. & Heslop, H. E. Post-transplant lymphoproliferative disorders. Annu Rev. Med 56, 29–44 (2005).
pubmed: 15660500
doi: 10.1146/annurev.med.56.082103.104727
Claeys, E. & Vermeire, K. Immunosuppressive drugs in organ transplantation to prevent allograft rejection: Mode of action and side effects. J. Immunol. Sci. 3, 14–21 (2019).
doi: 10.29245/2578-3009/2019/4.1178
Smith, C. & Khanna, R. Adoptive therapy for EBV-induced cancers: driving success with post-transplant lymphoproliferative disorder to other EBV-derived tumors. Immunotherapy 7, 563–572 (2015).
pubmed: 26065480
doi: 10.2217/imt.15.7
Wood, C. & Harrington, W. AIDS and associated malignancies. Cell Res. 15, 947–952 (2005).
pubmed: 16354573
doi: 10.1038/sj.cr.7290372
Engels, E. A. et al. Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS 20, 1645–1654 (2006).
pubmed: 16868446
doi: 10.1097/01.aids.0000238411.75324.59
Ramaswami, R. et al. Evolution of HIV-Associated Lymphoma Over 3 Decades. JAIDS J. Acquired Immune Defic. Syndromes 72, 177–183 (2016).
doi: 10.1097/QAI.0000000000000946
Powles, T. et al. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman’s disease. Ann. Oncol. 20, 775–779 (2009).
pubmed: 19179554
doi: 10.1093/annonc/mdn697
Brugnaro, P. Non-AIDS definings malignancies among human immunodeficiency virus-positive subjects: Epidemiology and outcome after two decades of HAART era. World J. Virol. 4, 209 (2015).
pubmed: 26279983
pmcid: 4534813
doi: 10.5501/wjv.v4.i3.209
Damania, B. & Münz, C. Immunodeficiencies that predispose to pathologies by human oncogenic γ-herpesviruses. FEMS Microbiol. Rev. 43, 181–192 (2019).
Deng, Y. et al. CD27 is required for protective lytic EBV antigen–specific CD8
pubmed: 33827115
pmcid: 8351885
doi: 10.1182/blood.2020009482
Strowig, T. et al. Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J. Exp. Med. 206, 1423–1434 (2009).
pubmed: 19487422
pmcid: 2715061
doi: 10.1084/jem.20081720
Yajima, M. et al. T Cell–Mediated Control of Epstein‐Barr Virus Infection in Humanized Mice. J. Infect. Dis. 200, 1611–1615 (2009).
pubmed: 19832115
doi: 10.1086/644644
Chijioke, O., Marcenaro, E., Moretta, A., Capaul, R. & Münz, C. Role of the 2B4 Receptor in CD8
pubmed: 25722295
doi: 10.1093/infdis/jiv114
Caduff, N. et al. Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice. PLoS Pathog. 16, e1008477 (2020).
pubmed: 32251475
pmcid: 7162544
doi: 10.1371/journal.ppat.1008477
Antsiferova, O. et al. Adoptive Transfer of EBV Specific CD8
pubmed: 25165855
pmcid: 4148450
doi: 10.1371/journal.ppat.1004333
Roshan, R. et al. T-cell responses to KSHV infection: a systematic approach. Oncotarget 8, 109402–109416 (2017).
pubmed: 29312617
pmcid: 5752530
doi: 10.18632/oncotarget.22683
Robey, R. C. et al. The CD8 and CD4 T-Cell Response against Kaposi’s Sarcoma-Associated Herpesvirus Is Skewed Towards Early and Late Lytic Antigens. PLoS One 4, e5890 (2009).
pubmed: 19536280
pmcid: 2691989
doi: 10.1371/journal.pone.0005890
Labo, N. et al. Heterogeneity and Breadth of Host Antibody Response to KSHV Infection Demonstrated by Systematic Analysis of the KSHV Proteome. PLoS Pathog. 10, e1004046 (2014).
pubmed: 24675986
pmcid: 3968157
doi: 10.1371/journal.ppat.1004046
Wang, L.-X. et al. Humanized-BLT mouse model of Kaposi’s sarcoma-associated herpesvirus infection. Proc. Natl Acad. Sci. 111, 3146–3151 (2014).
pubmed: 24516154
pmcid: 3939909
doi: 10.1073/pnas.1318175111
McHugh, D. et al. Persistent KSHV Infection Increases EBV-Associated Tumor Formation In Vivo via Enhanced EBV Lytic Gene Expression. Cell Host Microbe 22, 61–73.e7 (2017).
pubmed: 28704654
doi: 10.1016/j.chom.2017.06.009
Faure, A., Hayes, M. & Sugden, B. How Kaposi’s sarcoma-associated herpesvirus stably transforms peripheral B cells towards lymphomagenesis. Proc. Natl Acad. Sci. USA 116, 16519–16528 (2019).
pubmed: 31363046
pmcid: 6697783
doi: 10.1073/pnas.1905025116
Caduff, N. et al. KSHV infection drives poorly cytotoxic CD56-negative natural killer cell differentiation in vivo upon KSHV/EBV dual infection. Cell Rep. 35, 109056 (2021).
pubmed: 33951431
pmcid: 10285879
doi: 10.1016/j.celrep.2021.109056
Harris, D. T. & Badowski, M. Long term human reconstitution and immune aging in NOD-Rag (-)-γ chain (-) mice. Immunobiology 219, 131–137 (2014).
pubmed: 24094417
doi: 10.1016/j.imbio.2013.08.013
Lang, J. et al. Studies of Lymphocyte Reconstitution in a Humanized Mouse Model Reveal a Requirement of T Cells for Human B Cell Maturation. J. Immunol. 190, 2090–2101 (2013).
pubmed: 23335750
doi: 10.4049/jimmunol.1202810
Audigé, A. et al. Long-term leukocyte reconstitution in NSG mice transplanted with human cord blood hematopoietic stem and progenitor cells. BMC Immunol. 18, 28 (2017).
pubmed: 28558649
pmcid: 5450051
doi: 10.1186/s12865-017-0209-9
Meixlsperger, S. et al. CD141
pubmed: 23482932
pmcid: 3689250
doi: 10.1182/blood-2012-12-473413
Lysenko, V. et al. Humanised mouse models for haematopoiesis and infectious diseases. Swiss Med. Wkly. 147, w14516 (2017).
Gonzalez-Quintela, A. et al. Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities. Clin. Exp. Immunol. 151, 42–50 (2008).
pubmed: 18005364
pmcid: 2276914
doi: 10.1111/j.1365-2249.2007.03545.x
Mbisa, G. L. et al. Detection of antibodies to Kaposi’s sarcoma-associated herpesvirus: A new approach using K8.1 ELISA and a newly developed recombinant LANA ELISA. J. Immunol. Methods 356, 39–46 (2010).
pubmed: 20211626
pmcid: 2981141
doi: 10.1016/j.jim.2010.02.015
Nalwoga, A. et al. Kaposi’s sarcoma-associated herpesvirus T cell responses in HIV seronegative individuals from rural Uganda. Nat. Commun. 12, 7323 (2021).
pubmed: 34916520
pmcid: 8677732
doi: 10.1038/s41467-021-27623-8
Dunmire, S. K., Grimm, J. M., Schmeling, D. O., Balfour, H. H. & Hogquist, K. A. The Incubation Period of Primary Epstein-Barr Virus Infection: Viral Dynamics and Immunologic Events. PLoS Pathog 11, e1005286 (2015).
Hislop, A. D., Taylor, G. S., Sauce, D. & Rickinson, A. B. Cellular responses to viral infection in humans: Lessons from Epstein-Barr virus. Annu. Rev. Immunol. 25, 587–617 (2007).
Meckiff, B. J. et al. Primary EBV Infection Induces an Acute Wave of Activated Antigen-Specific Cytotoxic CD4
pubmed: 31308093
pmcid: 6697742
doi: 10.4049/jimmunol.1900377
Tomazin, R. et al. Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD4
pubmed: 10470081
doi: 10.1038/12478
Hegde, N. R. et al. Inhibition of HLA-DR Assembly, Transport, and Loading by Human Cytomegalovirus Glycoprotein US3: a Novel Mechanism for Evading Major Histocompatibility Complex Class II Antigen Presentation. J. Virol. 76, 10929–10941 (2002).
pubmed: 12368336
pmcid: 136637
doi: 10.1128/JVI.76.21.10929-10941.2002
Ressing, M. E. et al. Interference with T cell receptor-HLA-DR interactions by Epstein-Barr virus gp42 results in reduced T helper cell recognition. Proc. Natl Acad. Sci. USA 100, 11583–11588 (2003).
pubmed: 14504389
pmcid: 208801
doi: 10.1073/pnas.2034960100
Li, D. et al. Down-Regulation of MHC Class II Expression through Inhibition of CIITA Transcription by Lytic Transactivator Zta during Epstein-Barr Virus Reactivation. J. Immunol. 182, 1799–1809 (2009).
pubmed: 19201831
doi: 10.4049/jimmunol.0802686
Schmidt, K., Wies, E. & Neipel, F. Kaposi’s Sarcoma-Associated Herpesvirus Viral Interferon Regulatory Factor 3 Inhibits Gamma Interferon and Major Histocompatibility Complex Class II Expression. J. Virol. 85, 4530–4537 (2011).
pubmed: 21345951
pmcid: 3126280
doi: 10.1128/JVI.02123-10
Zuo, J., Hislop, A. D., Leung, C. S., Sabbah, S. & Rowe, M. Kaposi’s Sarcoma-Associated Herpesvirus-Encoded Viral IRF3 Modulates Major Histocompatibility Complex Class II (MHC-II) Antigen Presentation through MHC-II Transactivator-Dependent and -Independent Mechanisms: Implications for Oncogenesis. J. Virol. 87, 5340–5350 (2013).
pubmed: 23449805
pmcid: 3648188
doi: 10.1128/JVI.00250-13
Piskurich, J. F. et al. BLIMP-1 mediates extinction of major histocompatibility class II transactivator expression in plasma cells. Nat. Immunol. 1, 526–532 (2000).
pubmed: 11101876
doi: 10.1038/82788
Schmelz, M., Montes-Moreno, S., Piris, M., Wilkinson, S. T. & Rimsza, L. M. Lack and/or aberrant localization of major histocompatibility class II (MHCII) protein in plasmablastic lymphoma. Haematologica 97, 1614–6 (2012).
Sabbah, S. et al. T-cell immunity to Kaposi sarcoma-associated herpesvirus: recognition of primary effusion lymphoma by LANA-specific CD4
pubmed: 22234686
doi: 10.1182/blood-2011-07-366476
Sun, Z., Jha, H. C., Pei, Y. & Robertson, E. S. Major Histocompatibility Complex Class II HLA-DRα Is Downregulated by Kaposi’s Sarcoma-Associated Herpesvirus-Encoded Lytic Transactivator RTA and MARCH8. J. Virol. 90, 8047–8058 (2016).
pubmed: 27356905
pmcid: 5008100
doi: 10.1128/JVI.01079-16
Santarelli, R., Granato, M., Faggioni, A. & Cirone, M. Interference with the Autophagic Process as a Viral Strategy to Escape from the Immune Control: Lesson from Gamma Herpesviruses. J. Immunol. Res. 2015, 1–9 (2015).
doi: 10.1155/2015/546063
Broussard, G. & Damania, B. Regulation of KSHV Latency and Lytic Reactivation. Viruses 12, 1034 (2020)
Endres, M. J., Garlisi, C. G., Xiao, H., Shan, L. & Hedrick, J. A. The Kaposi’s Sarcoma–related Herpesvirus (KSHV)-encoded Chemokine vMIP-I is a Specific Agonist for the CC Chemokine Receptor (CCR)8. J. Exp. Med. 189, 1993–1998 (1999).
pubmed: 10377196
pmcid: 2192975
doi: 10.1084/jem.189.12.1993
Nakano, K. et al. Kaposi’s sarcoma-associated herpesvirus (KSHV)-encoded vMIP-I and vMIP-II induce signal transduction and chemotaxis in monocytic cells. Arch. Virol. 148, 871–890 (2003).
pubmed: 12721796
doi: 10.1007/s00705-002-0971-7
Casper, C. et al. KSHV (HHV8) vaccine: promises and potential pitfalls for a new anti-cancer vaccine. NPJ Vaccines 7, 108 (2022).
pubmed: 36127367
pmcid: 9488886
doi: 10.1038/s41541-022-00535-4
Delecluse, H. J., Hilsendegen, T., Pich, D., Zeidler, R. & Hammerschmidt, W. Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. Proc. Natl Acad. Sci. USA 95, 8245–8250 (1998).
pubmed: 9653172
pmcid: 20961
doi: 10.1073/pnas.95.14.8245
Kati, S. et al. Activation of the B Cell Antigen Receptor Triggers Reactivation of Latent Kaposi’s Sarcoma-Associated Herpesvirus in B Cells. J. Virol. 87, 8004–8016 (2013).
pubmed: 23678173
pmcid: 3700181
doi: 10.1128/JVI.00506-13
Kati, S. et al. Generation of high-titre virus stocks using BrK.219, a B-cell line infected stably with recombinant Kaposi’s sarcoma-associated herpesvirus. J. Virol. Methods 217, 79–86 (2015).
pubmed: 25736227
doi: 10.1016/j.jviromet.2015.02.022
Brulois, K. F. et al. Construction and Manipulation of a New Kaposi’s Sarcoma-Associated Herpesvirus Bacterial Artificial Chromosome Clone. J. Virol. 86, 9708–9720 (2012).
pubmed: 22740391
pmcid: 3446615
doi: 10.1128/JVI.01019-12
Berger, C. et al. Dynamics of Epstein-Barr virus DNA levels in serum during EBV-associated disease. J. Med Virol. 64, 505–512 (2001).
pubmed: 11468736
doi: 10.1002/jmv.1078
Tedeschi, R. et al. Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi’s sarcoma. J. Clin. Microbiol 39, 4269–4273 (2001).
pubmed: 11724831
pmcid: 88535
doi: 10.1128/JCM.39.12.4269-4273.2001
Ray, A. & Dittel, B. N. Isolation of mouse peritoneal cavity cells. J. Vis. Exp. 35, 1488 (2010).
Gros, A. et al. Recognition of human gastrointestinal cancer neoantigens by circulating PD-1
pubmed: 31609250
pmcid: 6819109
doi: 10.1172/JCI127967
Bolotin, D. A. et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat. Methods 12, 380–381 (2015).
pubmed: 25924071
doi: 10.1038/nmeth.3364
Shugay, M. et al. VDJtools: Unifying Post-analysis of T Cell Receptor Repertoires. PLoS Comput Biol. 11, e1004503 (2015).
pubmed: 26606115
pmcid: 4659587
doi: 10.1371/journal.pcbi.1004503
Nazarov, V. Immunarch. bot, Ruminskiy E. immunomind/immunarch: 0.6. 5: Basic single-cell support; 2020. Preprint.